Biomap, a biotechnology start-up co-established by Baidu founder Robin Li Yanhong and backed by the Hong Kong authorities, says it has surpassed Alphabet subsidiary AlphaFold in commercialising synthetic intelligence basis fashions for drug discovery.
Multinational pharmaceutical firms have been seeing a “reverse” within the technological hole between Biomap and AlphaFold, Wei Liu, co-founder and CEO of Biomap and former CEO of Baidu Ventures, stated in an interview with the South China Morning Put up.
“There is no absolute winner in AI benchmark exams, however when it comes to commercialisation and tasks developed primarily based on our fashions, I feel we’re forward of AlphaFold,” stated Wei. Nevertheless, AlphaFold had “larger tutorial affect”, he added.
Do you’ve gotten questions concerning the largest matters and developments from all over the world? Get the solutions with SCMP Data, our new platform of curated content material with explainers, FAQs, analyses and infographics delivered to you by our award-winning workforce.
Developed by London-based DeepMind – owned by Google’s guardian firm, Alphabet – AlphaFold is broadly thought of the worldwide chief in utilizing AI to analyse and predict molecular constructions and interactions to find new therapies.
Biomap is a part of a rising cohort of Chinese language corporations, together with start-ups and main tech firms like TikTok proprietor ByteDance, which might be difficult AlphaFold within the quickly evolving area. ByteDance has developed Protenix, a molecular construction prediction mannequin.
Baidu CEO Robin Li Yanhong is a co-founder of Biomap. Picture: EPA-EFE alt=Baidu CEO Robin Li Yanhong is a co-founder of Biomap. Picture: EPA-EFE>
Biomap reported final 12 months that its xTrimo fashions demonstrated larger accuracy than AlphaFold 3 in figuring out interactions between 70 antibodies and 44 single-domain antibodies with their targets.
Established in 2020, Biomap secured funding from the government-owned Hong Kong Funding Company (HKIC) in June final 12 months.
The partnership sought to boost the town’s biotech ecosystem by way of an accelerator programme known as BioMap InnoHub, which incubated greater than 10 tasks and two firms, with the purpose of increasing to greater than 50 tasks and 20 firms by 2030, Liu stated at an occasion co-hosted by the HKIC on Monday.
On Monday, Biomap additionally introduced the co-founding of a brand new firm in Hong Kong centered on bringing new medicine to market, furthering its commercialisation efforts.
BioGend Science – co-established with Legend Capital, a enterprise capital subsidiary of Lenovo Group’s guardian Legend Holdings – would develop a number of drug pipelines utilizing Biomap’s AI platform and Hong Kong’s analysis and medical sources, Liu stated in a speech.